Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6–73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients’ autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients 70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10−5), especially those <70 yr old (OR = 139.9, P = 3.1 × 10−10). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for ∼5% of cases of life-threatening influenza pneumonia in patients <70 yr old.
Andes virus (ANDV) is the leading cause of hantavirus cardiopulmonary syndrome (HCPS) in South America, a severe zoonosis with high mortality. Advances in critical care and extracorporeal membrane oxygenation (ECMO) have significantly improved survival rates; however, data on recovery beyond survival remain limited. This multicenter cohort study enrolled laboratory-confirmed HCPS survivors in Chile between 2021 and 2024, with follow-up at 3–6 months post-symptom onset to assess physical and neuropsychological sequelae. Participants were stratified by ECMO requirement and the clinical severity of HCPS, and evaluated using self-reported recovery, standardized symptom questionnaires, and EQ-5D quality-of-life instruments. Among 21 survivors (11 ECMO, 10 non-ECMO), 61.9% reported incomplete recovery. While 60–70% of patients received general medical follow-up, only 30% of non-ECMO patients—compared to all ECMO patients—had contact with a rehabilitation provider. Motor dysfunction and palpitations were more frequent in ECMO survivors; however, Jaccard index analysis revealed clustering of physical and neuropsychological symptoms across both groups. EQ-5D assessments showed comparable quality-of-life impairment, though non-ECMO survivors more often reported pain/discomfort (90.0% vs. 63.6%) and higher rates of analgesic self-medication. These findings highlight the burden of persistent symptoms after HCPS and the need for multidisciplinary post-discharge care in endemic regions.
Since the first report of SARS-CoV-2 infection in humans, the virus has mutated to develop new viral variants with higher infection rates and more resistance to neutralization by antibodies elicited after natural SARS-CoV-2 infection or by vaccines. Therefore, rapid identification of viral variants circulating in the population is crucial for epidemiological assessment and efforts to contain the resurgence of the pandemic. Between January and November 2021, we performed a large variant RT-qPCR-based screening of mutations in the spike protein of 1851 SARS-CoV-2-positive samples derived from outpatients from the UC-Christus Health Network in Chile. In a portion of samples (n = 636), we validated our RT-qPCR-pipeline by WGS, obtaining a 99.2% concordance. Our results indicate that from January to March 2021 there was a dominance of non-identifiable variants by the RT-qPCR-based screening; however, throughout WGS we were able to identify the Lambda (C.37) variant of interest (VOI). From March to July, we observed the rapid emergence of mutations associated with the Gamma variant (P.1), which was quickly replaced by the appearance of a combination of samples harboring mutations associated with the Delta variant (B.1.617.2), which predominated until the end of the study. Our results highlight the applicability of cost-effective RT-qPCR-based screening of mutations associated with known variants of concern (VOC), VOI and variants under monitoring (VUM) of SARS-CoV-2, being a rapid and reliable tool that complements WGS-based surveillance.
17 September 2025 in Current Research in Microbial Sciences
• ANDV can be isolated in cell culture only in the absence of neutralizing antibodies. • The monitoring of close contacts of ANDV cases allows to identify prospective cases. • We isolated a new ANDV human strain from an early blood sample of a secondary case. • CHI-Hu13724 is a different haplotype from the previous ANDV reference strains. • Isolation of currently zoonotic ANDV strains helps the study of viral pathogenicity.